Researchers at the University of Chicago have identified a new member of the tripartite motif (TRIM) family of proteins that could control the reactivation of several herpesviruses, including the cancer-associated Kaposi's sarcoma herpesvirus (KSHV).
Researchers at the University of Iowa have identified a protein fragment of the structural protein junctophilin-2 that could partially prevent pathological processes contributing to heart failure.
Researchers at the Dana-Farber Cancer Institute and the Swiss Friedrich Miescher Institute have developed a method to find compounds that will induce the degradation of zinc fingers, which collectively are thought to comprise the single largest group of transcription factors in the human proteome.
Researchers from MD Anderson Cancer Center have published new findings that argue for a role of the long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) as a metastasis suppressor, rather than promoter, as previous work had suggested.
The good news is that BACE-1 inhibitors hit their targets. In that sense, in fact, the class has been "incredibly successful," Bruce Albala, executive director of neuroscience clinical development in Eisai Inc.'s neurology business group, told the audience at a symposium titled "Is BACE1 a suitable drug target for prevention and treatment of Alzheimer's disease?" at the 2018 Clinical Trials in Alzheimer's Disease (CTAD) meeting.
BARCELONA, Spain – Presenters and panelists alike tried to make the best of a bad situation at the opening session of the 2018 Clinical Trials in Alzheimer's Disease (CTAD) meeting, lauding the open discussion, collaboration and potential scientific gains to be had from the continued analysis of the discontinued Alzheimer's disease (AD) trials APECS, EARLY and NAVIGATE-AD.
MUNICH – With more than three years of follow-up, median progression-free survival (PFS) has yet to be reached in the treatment arm of the SOLO-1 study. Patients receiving placebo had a median progression-free survival (PFS) of 13.8 months, making for a hazard ratio of 0.3 and data that seem likely to turn Lynparza (olaparib, Astrazeneca plc) into the front-line standard of care for women with BRCA mutations.
